Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Zomedica vs. Zoetis: Which Pet Stock is a Better Buy?

Published 04/29/2021, 11:06 AM
Updated 04/29/2021, 12:31 PM
© Reuters.  Zomedica vs. Zoetis: Which Pet Stock is a Better Buy?

© Reuters. Zomedica vs. Zoetis: Which Pet Stock is a Better Buy?

A surge in pet adoptions and acquisitions amid the COVID-19 pandemic has increased the demand for pet care products and veterinary services. Indeed, remote working dynamics are said to have deepened human-pet bonds, which is contributing in-part to increased pet care spending. The trend has bolstered the performance of pet care companies Zomedica (ZOM) and Zoetis (ZTS). But let’s find out which of these stocks is a better buy now.Zomedica Corp. (ZOM) and Zoetis Inc . (NYSE:ZTS) are two popular veterinary healthcare companies engaged in the development, manufacture, and commercialization of animal health medicines in the United States and internationally. ZOM’s lead drug product candidate ZM-007 is used for the treatment of acute diarrhea in small dog breeds and puppies. ZTS offers vaccines to prevent respiratory, gastrointestinal and reproductive tract diseases.

With people spending far more time at home, coping with stress and isolation amid the pandemic, there has been a significant increase in pet ownership. This has driven a surge in demand for pet care services, diagnostics and medicine. Since pet owners are now paying more attention to their companions’ health and wellness, and spending more on medical care amid the uncertainties surrounding the pandemic, the demand for veterinary services is expected to grow even more in the coming months. This bodes well for ZOM and ZTS.

While ZOM lost 34.9% over the last month, ZTS surged 8.7%. However, in terms of their past year’s performance, ZOM’s 570.7% makes it a clear winner given ZTS’ 33.2% returns. But, which of these stocks is a better pick now? Let’s find out.

Continue reading on StockNews

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.